$CE

Celanese (CE) stock is slipping after a recent rally driven by a bullish analyst call and debt-reduction optimism. Investors are locking in profits, and the company's heavy debt load and recent profitability hit may pressure the stock. Celanese's strong free cash flow supports debt reduction and growth investments, but margin recovery risks remain.

Major indices closed lower Thursday, with the Russell 2000 down 1.04%. Brent Crude surged 7.2% to $108.60 due to U.S.-Iran tensions. Morgan Stanley downgraded Novo Nordisk (NVO) to Underweight, while RBC initiated Dell (DELL) with an Outperform rating and $640 target. Analysts also made calls on Atmos Energy (ATO), Celanese (CE), Check Point (CHKP), Chewy (CHWY), Fortinet (FTNT), Global Payments (GPN), HP (HPQ), and Shopify (SHOP).

KeyBanc initiated coverage on Celanese (NYSE: CE) with an overweight rating and a $57 price target, citing attractive valuation and strong free cash flow yield. The firm estimates the company has sufficient liquidity to repay debt through 2028. Celanese's Q2 2026 earnings beat estimates but revenue missed slightly, with a cautious outlook due to restructuring and leverage concerns.

Celanese (CE) is selling 19% of Nutrinova to Mitsui for $152M, reducing its stake to 11%. The sale, expected to close Q4, will help reduce debt and fund maturities, part of a $1B divestiture goal by 2027. The sold stake generated $4M in 2025 earnings, implying a 38x multiple.

Mitsui & Co. will integrate upstream operations at VP4, a German producer of key intermediates for Nutrinova's food ingredients. Mitsui will acquire an additional 19% stake in Nutrinova from Celanese, increasing its holding to 89% and making Nutrinova a consolidated subsidiary. This move aims to secure supply, improve cost competitiveness, and align with Mitsui's growth strategy in the Food Science business.

Celanese (NYSE: CE) will sell an additional 19% stake in Nutrinova to Mitsui for $152M, retaining an 11% interest. The deal supports its deleveraging plans and is expected to close in Q4. Celanese will operate a diketene facility for Nutrinova, receiving the purchase price and operating costs.

Celanese Corp (CE) partnered with VIGOR Precision to develop lightweight plastic joints for humanoid robots, aiming to reduce weight by 30%. CE will supply materials and technical support, targeting industrial and service robotics. CE's shares gained 3.5% over the past year, outperforming its industry. The company holds a Zacks Rank #3 (Hold).

Kyrish Chuck (SVP & CFO) purchased 2,300 shares of Celanese Corp (CE) at an average of $45.52 ($45.50–$45.53, $0.10M total) across 3 trades on 2026-08-14.

Celanese and Vigor Precision formed a strategic partnership to develop lightweight plastic joint components for humanoid robots. Celanese will supply engineering plastics and technical support, while Vigor will provide precision plastic gears and components. The goal is to cut joint-module weight by more than 30% versus metal designs while maintaining strength and precision. Celanese reported $9.5B net sales in 2025.

Simply Wall St reports Celanese’s Q2 2026 results: sales rose to $2,752 million from $2,532 million, while net income and EPS fell year over year. The article notes choppy shares, with a 90-day decline of 19.61%. It cites a fair value narrative of $68.70 versus a $45.66 close, implying undervaluation, but flags industry overcapacity and elevated debt.